Benzinga | Oct 30, 2020 08:08AM EDT

Horizon Therapeutics To Present TEPEZZA Data At American Academy Of Ophthalmology Annual Meeting Nov. 13-15

-- Oral presentation will highlight results from the OPTIC 48-week off-treatment follow-up period, including long-term proptosis (eye bulging) response and diplopia (double vision) improvement --

-- Poster presentation assesses improvement in fellow eye of patients with TED, indicating potential benefits in less severe disease --

Horizon Therapeutics plc (NASDAQ:HZNP) today announced new TEPEZZA(r) (teprotumumab-trbw) data being presented at the American Academy of Ophthalmology Annual Meeting (AAO 2020 Virtual), Nov. 13-15, 2020. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED -- a serious, progressive and vision-threatening rare autoimmune disease.1

TEPEZZA data being presented at AAO 2020 Virtual include:

* Long-Term Assessment of Proptosis and Diplopia from the OPTIC Trial of Teprotumumab in Thyroid Eye Disease Session: PA038, R. Douglas Date: On Demand (oral presentation)

* Improvement in the Fellow Eye of Patients With TED: Pooled Analyses from the Teprotumumab Studies Session: PO305, R. Douglas Date: On Demand (scientific poster)

* Dysthyroid Optic Neuropathy Response to Teprotumumab: Early Response to Therapy Session: PO307, C. Sears Date: On Demand (scientific poster) Independent study

* What Every Ophthalmologist Should Know About Teprotumumab Session: OCU03V, R. Douglas Date: Friday, Nov. 13, 2020; 1:07 p.m. PT (live broadcast)

* Plastics: Biologics for Orbital Disease (teprotumumab) Session: SYM17V, R. Douglas Date: Sunday, Nov. 15, 2020; 2:05 p.m. PT (live broadcast)

In addition, Horizon will host a virtual product theater on Friday, Nov. 13 at 4:30 p.m. PT about TEPEZZA, featuring Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center.